Company Overview - Recludix Pharma is a leader in discovering inhibitors for challenging targets related to inflammatory diseases [1][3] - The management team consists of industry veterans with experience from companies like Seagen, Blueprint Medicines, and Lilly [3] - The company has developed a unique drug discovery platform that includes custom DNA-encoded libraries and proprietary screening tools [3] Key Programs - The most advanced program focuses on STAT6 inhibitors, which are relevant for diseases such as atopic dermatitis, asthma, rheumatoid arthritis, and chronic spontaneous urticaria [3] - Recludix has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor [3] - The company plans to submit an Investigational New Drug application for its STAT6 inhibitor REX-8756 in 2025 [3] - Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor targeting B cell or mast cell-driven inflammatory and immune diseases [3] Upcoming Events - Key executives will participate in the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025 [1] - An overview of the company will be presented during the forum at 3:00 p.m. Eastern Time [1]